Monoclonal Antibodies

Photo: Samuel Ramos on Unsplash

Monoclonal antibody treatments:

Intravenous:

Briumvi is given every 6 months though the vein to remove B immune cells which can attack the brain, spinal cord and optic nerves.

Lemtrada  is given in the vein over 5 days Year 1 and 3 days Year 2 to reset the immune system to reduce the risk of future disability.

Ocrevus  is given every 6 months in the vein to remove B cells which are involved in the immune attack in multiple sclerosis

Tysabri  is given every 4 weeks to the vein to block certain white blood cells from getting into the brain and spinal cord.

Novantrone (mitoxantrone) is a chemo medication (not an antibody) that is no longer used to treat MS due to risks of leukemia and heart damage.

Subcutaneous (under skin):

Kesimpta is self-injected under the skin every 4 weeks to remove B cells with goal of decreasing relapses and disability progression.